Predictors of participant engagement and naloxone utilization in a community-based naloxone distribution program

Addiction

Volumn 110, Issue 8, 2015, Pages 1301-1310

  Rowe, Christopher ^a   Santos, Glenn Milo ^b,c   Vittinghoff, Eric ^c   Wheeler, Eliza ^d   Davidson, Peter ^e   Coffin, Philip O ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Drug Overdose Prevention and Education Project   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Harm reduction; Heroin; Methamphetamine; Naloxone; Opiates; Overdose; Substance use

Indexed keywords

NALOXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ADULT; CALIFORNIA; COMPARATIVE STUDY; DRUG DEPENDENCE TREATMENT; DRUG OVERDOSE; EPIDEMIOLOGY; FEMALE; HUMAN; MALE; MENTAL HEALTH SERVICE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PATIENT ATTITUDE; STATISTICS AND NUMERICAL DATA;

ADULT; ANALGESICS, OPIOID; COMMUNITY MENTAL HEALTH SERVICES; DRUG OVERDOSE; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; NALOXONE; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PATIENT ACCEPTANCE OF HEALTH CARE; SAN FRANCISCO; SUBSTANCE ABUSE TREATMENT CENTERS;

EID: 84936984637     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12961     Document Type: Article

References (32)

1. Mortality G. B. D. Causes of Death C Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385: 117-71.
2. Centers for Disease Control and Prevention (CDC). Prescription Drug Overdose. Atlanta, GA: CDC; 2014.
3. Centers for Disease Control and Prevention (CDC). Policy Impact: Prescription Painkiller Overdoses. Atlanta, GA: CDC; 2014.
4. Warner M., Chen L. H., Makuc D. M., Anderson R. N., Minino A. M. Drug Poisoning Deaths in the United States, 1980-2008. In: National Center for Health Statistics (NCHS) data brief. Atlanta, GA: Centers for Disease Control and Prevention; 2011, pp. 1-8.
5. Calcaterra S., Glanz J., Binswanger I. A. National trends in pharmaceutical opioid related overdose deaths compared to other substance related overdose deaths: 1999-2009. Drug Alcohol Depend 2013; 131: 263-70.
6. Centers for Disease C., Prevention Community-based opioid overdose prevention programs providing naloxone-United States, 2010. Morb Mortal Wkly Rep 2012; 61: 101-5.
7. Davis C., Webb D., Burris S. Changing law from barrier to facilitator of opioid overdose prevention. J L Med Ethics J Am Soc L Med Ethics 2013; 41: 33-6.
8. Coffin P. O., Sullivan S. D. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med 2013; 158: 1-9.
9. Clark A. K., Wilder C. M., Winstanley E. L. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med 2014; 8: 153-63.
10. Chamberlain J. M., Klein B. L. A comprehensive review of naloxone for the emergency physician. Am J Emerg Med 1994; 12: 650-60.
11. Dahan A., Aarts L., Smith T. W. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology 2010; 112: 226-38.
12. World Health Organization (WHO) WHO Model List of Essential Medicines, 18th edn. Geneva, Switzerland: WHO; 2013.
13. World Health Organization (WHO) Consolidated Guidelines on HIV Prevention, Treatment and Care for Key Populations. Geneva, Switzerland: World Health Organization; 2014.
14. Sporer K. A., Kral A. H. Prescription naloxone: a novel approach to heroin overdose prevention. Ann Emerg Med 2007; 49: 172-7.
15. Walley A. Y., Xuan Z., Hackman H. H., Quinn E., Doe-Simkins M., Sorensen-Alawad A. et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ 2013; 346: f174.
16. Maxwell S., Bigg D., Stanczykiewicz K., Carlberg-Racich S. Prescribing naloxone to actively injecting heroin users: a program to reduce heroin overdose deaths. J Addict Dis 2006; 25: 89-96.
17. Doe-Simkins M., Walley A. Y., Epstein A., Moyer P. Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose. Am J Public Health 2009; 99: 788-91.
18. Enteen L., Bauer J., McLean R., Wheeler E., Huriaux E., Kral A. H. et al. Overdose prevention and naloxone prescription for opioid users in San Francisco. J Urban Health Bull NY Acad Med 2010; 87: 931-41.
19. Bennett A. S., Bell A., Tomedi L., Hulsey E. G., Kral A. H. Characteristics of an overdose prevention, response, and naloxone distribution program in Pittsburgh and Allegheny County, Pennsylvania. J Urban Health Bull NY Acad Med 2011; 88: 1020-30.
20. Binswanger I. A., Blatchford P. J., Mueller S. R., Stern M. F. Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med 2013; 159: 592-600.
21. Coffin P. O., Tracy M., Bucciarelli A., Ompad D., Vlahov D., Galea S. Identifying injection drug users at risk of nonfatal overdose. Acad Emerg Med 2007; 14: 616-23.
22. Warner M., Chen L. H., Makuc D. M. Increase in Fatal Poisonings Involving Opioid Analgesics in the United States, 1999-2006. In: National Center for Health Statistics (NCHS) data brief. Atlanta, GA: Centers for Disease Control and Prevention; 2009, pp. 1-8.
23. Jenkins L. M., Banta-Green C. J., Maynard C., Kingston S., Hanrahan M., Merrill J. O., et al. Risk factors for nonfatal overdose at Seattle-area syringe exchanges. J Urban health Bull NY Acad Med 2011; 88: 118-28.
24. Fisher J. D., Fisher W. A. Changing AIDS-risk behavior. Psychol Bull 1992; 111: 455-74.
25. Fisher W. A., Fisher J. D., Harman J. The Information-Motivation-Behavioral Skills model: a general social psychological approach to understanding and promoting health behavior. In: Suls J., Wallston K. A., editors. Social Psychological Foundations of Health and Illness. Malden, MA: Blackwell 2003, pp. 82-106.
26. Bohnert A. S., Tracy M., Galea S. Circumstances and witness characteristics associated with overdose fatality. Ann Emerg Med 2009; 54: 618-24.
27. Marsch L. A. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction 1998; 93: 515-32.
28. Hart A. Fiscal Year 2013-2014. Annual Report for FY 2010-2011. Office of the Chief Medical Examiner City and County of San Francisco: San Francisco, CA; 2013.
29. US Census Bureau State and County QuickFacts. Washington, DC: US Census Bureau; 2014.
30. Davidson P. J., McLean R. L., Kral A. H., Gleghorn A. A., Edlin B. R., Moss A. R. Fatal heroin-related overdose in San Francisco, 1997-2000: a case for targeted intervention. J Urban Health Bull NY Acad Med 2003; 80: 261-73.
31. Hart A. Annual Report for July 2002 to June 2003. Office of the Chief Medical Examiner City and County of San Francisco: San Francisco, CA; 2004.
32. Substance Abuse and Mental Health Services Administration (SAMHSA). Drug Abuse Warning Network, 2011 Emergency Department Excel Files, Metro Division, San Francisco. In: Div_2011_AllMA S. S., editor. Rockville, MD: Office of Applied Studies, SAMHSA; 2011.